Osmotica Pharmaceuticals plc (NASDAQ:OSMT) management will conduct a conference call for 11th August 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.osmotica.com
Earnings Expectation
Osmotica Pharmaceuticals plc is reporting second quarter financial results on Tuesday 11th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, OSMT is expected to report 2Q20 loss of $ 0.12 per share from revenue of $ 40.83 million. For the full year, analysts anticipate top line of $ 172.22 million, while looking forward to loss of $ 0.59 per share bottom line.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The companys promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinsons and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides womens health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos.
